Last10K.com

Iqvia Holdings Inc. (IQV) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Iqvia Holdings Inc.

CIK: 1478242 Ticker: IQV

Exhibit 99.1

IQVIA Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance

  • Revenue $2,594 million, up 6.3 percent at constant currency and 5.2 percent reported
  • Adjusted EBITDA $561 million, up 8.4 percent at constant currency and 9.4 percent reported
  • GAAP Diluted Earnings per Share $0.29
  • Adjusted Diluted Earnings per Share $1.42, up 19.3 percent
  • $792 million of share repurchase completed year-to-date; $133 million during the third quarter
  • Record quarter of R&D Solutions contracted services Net New Business, resulting in a book-to-bill ratio of 1.69x
  • Reaffirming mid-point of full-year 2018 revenue guidance inclusive of foreign currency headwind; raising mid-point of full-year 2018 Adjusted EBITDA and Adjusted Diluted EPS guidance

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--October 22, 2018--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2018. On January 1, 2018, IQVIA adopted ASC 606 “Revenue from Contracts with Customers” as required by the Financial Accounting Standards Board. Under this new standard, IQVIA recognizes revenue in the Research & Development Solutions segment on a percentage of completion basis. Additionally, ASC 606 requires that service revenue and reimbursed expense revenue be consistently presented as one line on the income statement. Unless stated otherwise, all financial information that follows has been provided under ASC 606.

Third-Quarter 2018 Operating Results

Revenue for the third quarter of $2,594 million increased 6.3 percent at constant currency and 5.2 percent reported, compared to the third quarter of 2017. Technology & Analytics Solutions (TAS) revenue of $1,014 million grew 15.0 percent at constant currency and 12.9 percent reported, including the benefit of acquisitions. Research & Development Solutions (R&DS) revenue of $1,382 million grew 3.5 percent at constant currency and 3.1 percent reported, with growth in R&DS substantially all organic. Contract Sales & Medical Solutions (CSMS) revenue of $198 million declined 11.9 percent at constant currency and 12.8 percent reported.

Third-quarter 2018 Adjusted EBITDA of $561 million increased 8.4 percent at constant currency and 9.4 percent reported. GAAP net income was $60 million and GAAP diluted earnings per share was $0.29. Adjusted Net Income of $294 million grew 13.1 percent, and Adjusted Diluted Earnings per Share of $1.42 grew 19.3 percent.


The following information was filed by Iqvia Holdings Inc. (IQV) on Monday, October 22, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Iqvia Holdings Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Iqvia Holdings Inc..

Continue

Assess how Iqvia Holdings Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Iqvia Holdings Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Comprehensive Income (Unaudited)
Condensed Consolidated Statements Of Comprehensive Income (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Income (Unaudited)
Business Combinations
Business Combinations (Tables)
Business Combinations - Schedule Of Preliminary Allocation Of Purchase To Certain Intangible Assets Acquired And Goodwill (Detail)
Business Combinations - Schedule Of Preliminary Allocation Of Purchase To Certain Intangible Assets Acquired And Goodwill (Parenthetical) (Detail)
Comprehensive Income
Comprehensive Income (Tables)
Comprehensive Income - Summary Of Adjustments For (Gains) Losses Reclassified From Aoci Into Condensed Consolidated Statements Of Income And Affected Financial Statement Line Item (Detail)
Comprehensive Income - Summary Of Components Of Aoci (Detail)
Credit Arrangements
Credit Arrangements (Tables)
Credit Arrangements - Additional Information (Detail)
Credit Arrangements - Contractual Maturities Of Long-Term Debt (Detail)
Credit Arrangements - Summary Of Credit Facilities (Detail)
Credit Arrangements - Summary Of Debt (Detail)
Credit Arrangements - Summary Of Debt (Parenthetical) (Detail)
Derivatives
Derivatives (Tables)
Derivatives - Additional Information (Detail)
Derivatives - Effect Of Cash Flow Hedging Instruments On Other Comprehensive (Loss) Income (Detail)
Derivatives - Summary Of Fair Values Of Derivative Instruments Designated As Hedges (Detail)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Summary Of Weighted-Average Outstanding Stock Based Awards Excluded From Computation Of Diluted Earnings Per Share (Detail)
Employee Benefit Plans
Employee Benefit Plans (Tables)
Employee Benefit Plans - Summary Of Components Of Net Periodic Benefit Cost For Pension Benefits (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Changes In Level 3 Financial Assets And Liabilities Measured On Recurring Basis (Detail)
Fair Value Measurements - Fair Value Of Financial Assets And Liabilities Measured On Recurring Basis (Detail)
Goodwill
Goodwill (Tables)
Goodwill - Summary Of Goodwill By Reportable Segment (Detail)
Income Taxes
Income Taxes - Additional Information (Detail)
Investments - Debt, Equity And Other Securities - Additional Information (Detail)
Investments-Debt, Equity And Other Securities
Restructuring
Restructuring (Tables)
Restructuring - Summary Of Amounts Recorded For Restructuring Plans (Detail)
Revenues By Geography, Concentration Of Credit Risk And Remaining Performance Obligations
Revenues By Geography, Concentration Of Credit Risk And Remaining Performance Obligations (Tables)
Revenues By Geography, Concentration Of Credit Risk And Remaining Performance Obligations - Additional Information 1 (Detail)
Revenues By Geography, Concentration Of Credit Risk And Remaining Performance Obligations - Additional Information 2 (Detail)
Revenues By Geography, Concentration Of Credit Risk And Remaining Performance Obligations - Summary Of Revenues By Geographic Region And Reportable Segment (Detail)
Segments
Segments (Tables)
Segments - Additional Information (Detail)
Segments - Operations By Reportable Segments (Detail)
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity - Additional Information (Detail)
Stockholders' Equity - Summary Of Non-Controlling Interests (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Effect Of Adoption Of Asu 2014-09 On Condensed Consolidated Balance Sheet (Detail)
Summary Of Significant Accounting Policies - Effect Of Adoption Of Asu 2017-07 And Asu 2014-09 On Condensed Consolidated Statements Of Income (Detail)
Trade Accounts Receivable, Unbilled Services And Unearned Income
Trade Accounts Receivable, Unbilled Services And Unearned Income (Tables)
Trade Accounts Receivable, Unbilled Services And Unearned Income - Additional Information (Detail)
Trade Accounts Receivable, Unbilled Services And Unearned Income - Schedule Of Net Contract Assets (Liabilities) (Detail)
Trade Accounts Receivable, Unbilled Services And Unearned Income - Trade Accounts Receivable And Unbilled Services (Detail)
Variable Interest Entities
Variable Interest Entities (Tables)
Variable Interest Entities - Additional Information (Detail)
Variable Interest Entities - Summary Of Investments In Unconsolidated Variable Interest Entities And Estimated Maximum Exposure To Loss (Detail)

Material Contracts, Statements, Certifications & more

Iqvia Holdings Inc. provided additional information to their SEC Filing as exhibits

Ticker: IQV
CIK: 1478242
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-18-025117
Submitted to the SEC: Thu Oct 25 2018 4:11:35 PM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Sunday, September 30, 2018
Industry: Commercial Physical And Biological Research

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/iqv/0001564590-18-025117.htm